Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFa Agents

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data

Results Back to top ↑

Contact Back to top ↑

Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. Please note: Trial data is sourced from multiple external providers and as such UKCTG is not responsible for, and cannot guarantee, the accuracy of data, including Location information. Please contact us if you have any query regarding the quality of trial records.